Unlocking gene control mechanisms to develop small molecule therapies


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.


Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

October 11, 2017
Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

September 25, 2017
Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference

September 5, 2017
Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner